-The Economic Times Drug companies paid as little as 50,000 as compensation to families of volunteers who died during clinical trials for new medicines last year, leading to sharp criticism about the paltry sums being handed out and growing clamour among health groups for more stringent guidelines on new drug trials.  According to government data accessed by a healthcare activist through an RTI query, Germany's Fresenius Kabi paid 50,000 each to the...

-Down to Earth   Punjab has been in the grip of cancer for over a decade but the government has ignored the threat.  It all started with a knot in her left breast. Within no time it grew to the size of a tennis ball. In pain, 40-year-old Raj Rani went to the doctor in her village in Punjab’s Ferozepur district. Finding no relief, she started doing the rounds of government hospitals in...

-The Telegraph Dispur has decided to provide free treatment to children below 12 years who are suffering from blood cancer or leukaemia. Health minister Himanta Biswa Sarma today said Dispur was working on the project and hoped to launch it on Independence Day. He told this correspondent that considering the huge cost of treatment for leukaemia, the government was also considering free treatment for adults below poverty line and subsidised rates for those...

It is said that only God and a few good men and women run India. One such man is P H Kurien. For readers unfamiliar with his name, Kurien was India's Controller General of Patents, Designs & Trade Marks until March 12, 2012. On March 9, 2012, just three days before he left office, he issued the first-ever compulsory licence in India for the manufacture of a drug still under patent....

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...